Home  >  Products  >  GCK (glucokinase (hexokinase 4) ) Blocking Peptide (the N terminal of GCK)(100ug)
GCK (glucokinase (hexokinase 4) ) Blocking Peptide (the N terminal of GCK)(100ug)

GCK (glucokinase (hexokinase 4) ) Blocking Peptide (the N terminal of GCK)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-GCK Antibody (ARP61473_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP61473
Size: 100ug
Weight: 51kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Alternative splicing of this gene results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in this gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young, type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI).
Alternative names: FGQTL3; GK; GLK; HHF3; HK4; HKIV; HXKP; MODY2
See Full Product Listings >